KR101656536B1 - 페오니플로린 제제 및 지방 감소를 위한 그의 용도 - Google Patents

페오니플로린 제제 및 지방 감소를 위한 그의 용도 Download PDF

Info

Publication number
KR101656536B1
KR101656536B1 KR1020107029010A KR20107029010A KR101656536B1 KR 101656536 B1 KR101656536 B1 KR 101656536B1 KR 1020107029010 A KR1020107029010 A KR 1020107029010A KR 20107029010 A KR20107029010 A KR 20107029010A KR 101656536 B1 KR101656536 B1 KR 101656536B1
Authority
KR
South Korea
Prior art keywords
fat
amount
adipocytes
expression
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107029010A
Other languages
English (en)
Korean (ko)
Other versions
KR20110138322A (ko
Inventor
바크르 라비
Original Assignee
바크르 라비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바크르 라비 filed Critical 바크르 라비
Publication of KR20110138322A publication Critical patent/KR20110138322A/ko
Application granted granted Critical
Publication of KR101656536B1 publication Critical patent/KR101656536B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0452—Specially adapted for transcutaneous muscle stimulation [TMS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N2007/0004—Applications of ultrasound therapy
    • A61N2007/0008—Destruction of fat cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Electrotherapy Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
KR1020107029010A 2008-05-23 2009-05-25 페오니플로린 제제 및 지방 감소를 위한 그의 용도 Expired - Fee Related KR101656536B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/126,246 US7943187B2 (en) 2008-05-23 2008-05-23 Paeoniflorin preparations and uses thereof for fat reduction
US12/126,246 2008-05-23

Publications (2)

Publication Number Publication Date
KR20110138322A KR20110138322A (ko) 2011-12-27
KR101656536B1 true KR101656536B1 (ko) 2016-09-12

Family

ID=41342622

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107029010A Expired - Fee Related KR101656536B1 (ko) 2008-05-23 2009-05-25 페오니플로린 제제 및 지방 감소를 위한 그의 용도

Country Status (9)

Country Link
US (4) US7943187B2 (enExample)
EP (1) EP2300018B1 (enExample)
JP (1) JP5507549B2 (enExample)
KR (1) KR101656536B1 (enExample)
CN (1) CN102170888B (enExample)
AU (2) AU2009345773A1 (enExample)
CA (1) CA2725972A1 (enExample)
DK (1) DK2300018T3 (enExample)
WO (1) WO2010127470A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943187B2 (en) * 2008-05-23 2011-05-17 Bakr Rabie Paeoniflorin preparations and uses thereof for fat reduction
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US20130012840A1 (en) * 2010-03-23 2013-01-10 Real Aesthetics Ltd. System and method for accelerating the relative proportion of fat catabolism
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
AU2014340351B2 (en) 2013-10-21 2020-01-30 Alevere Medical Corporation Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof
US20170119794A1 (en) * 2015-11-04 2017-05-04 Kythera Biopharmaceuticals, Inc. Treatments of accumulated fat with deoxycholic acid and salts thereof
US20200397820A1 (en) 2018-02-09 2020-12-24 Kohaku Bio Technology Co., Ltd. Glycerol Release Promoter
KR102392292B1 (ko) 2021-07-21 2022-05-03 중앙대학교 산학협력단 페오니플로린을 포함하는 악액질 및 근손실 예방 또는 치료용 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6485990A (en) * 1987-09-28 1989-03-30 Tsumura & Co Antihypertestoeronemia agent
US4888354A (en) * 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
US5919621A (en) * 1991-10-24 1999-07-06 Brown; David B. Methods for diagnosing human male infertility
IL101387A (en) * 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US5480772A (en) * 1993-02-03 1996-01-02 Brandeis University In vitro activation of a nucleus
FR2717382B1 (fr) * 1994-03-21 1996-06-07 Fabre Pierre Cosmetique Extraits de Paeonia Lactiflora titré en paeoniflorine utiles en cosmétologie dans le traitement capillaire.
PE17897A1 (es) * 1995-02-17 1997-06-12 Lilly Co Eli Formulacion transdermica en parche del 3-(4-butiltio)-1,2,5-tiadiazol-3-il)-1-azabiciclo (2,2,2) octano
US5698199A (en) * 1995-03-10 1997-12-16 Kao Corporation Lipolysis acceleration method
ATE218348T1 (de) 1997-10-08 2002-06-15 Genesiscosmetics Rights & Lice Straffung und/oder verkleinerung von fettzellen- haltigen körperpartien
US6638064B1 (en) * 2000-06-07 2003-10-28 Robert Scott Nance Flexible endodontic syringe
NZ529029A (en) * 2001-04-20 2005-07-29 Alza Corp Microprojection array having a beneficial agent containing coating
CN2560367Y (zh) * 2001-08-30 2003-07-16 夏勤 适于喉部和气管滴入药物的针头
US20030175328A1 (en) * 2002-03-06 2003-09-18 Adi Shefer Patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients into the skin
JP2004217583A (ja) * 2003-01-16 2004-08-05 Naris Cosmetics Co Ltd 痩身用皮膚外用剤
US20040191330A1 (en) * 2003-03-31 2004-09-30 Keefe Candace R. Daily skin care regimen
CN1555806A (zh) * 2003-12-31 2004-12-22 昆明同持医药研究有限公司 一种芍药甙注射剂及其制备方法和应用
KR20050107649A (ko) * 2004-05-10 2005-11-15 주식회사 엘지생활건강 페오니플로린을 포함하는 피부 노화 억제용 조성물
KR100769580B1 (ko) * 2005-03-07 2007-10-23 주식회사 엘지생활건강 자외선에 의한 피부 ｄｎａ 손상 방지제
US20080194496A1 (en) * 2004-05-10 2008-08-14 Lg Household & Health Care Ltd. Skin Aging Treatment Comprising Paeoniflorin
ES2372499T3 (es) 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
US7530958B2 (en) * 2004-09-24 2009-05-12 Guided Therapy Systems, Inc. Method and system for combined ultrasound treatment
JP4974533B2 (ja) * 2006-01-30 2012-07-11 富士フイルム株式会社 ジスルフィド架橋したタンパク質ナノ粒子
US20080294072A1 (en) * 2007-05-24 2008-11-27 Crutchfield Dermatology Mesotherapy with ultrasound
US7943187B2 (en) * 2008-05-23 2011-05-17 Bakr Rabie Paeoniflorin preparations and uses thereof for fat reduction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Fitoterapia. 2004. Vol.75, pp.45-49.*
International Journal of Pharmaceutics. 2003. Vol.257, pp.169-180.*

Also Published As

Publication number Publication date
JP2011523950A (ja) 2011-08-25
KR20110138322A (ko) 2011-12-27
US20150018906A1 (en) 2015-01-15
US20170216333A1 (en) 2017-08-03
US7943187B2 (en) 2011-05-17
CN102170888A (zh) 2011-08-31
CN102170888B (zh) 2013-06-19
US20110218163A1 (en) 2011-09-08
HK1159477A1 (en) 2012-08-03
WO2010127470A1 (en) 2010-11-11
US9901591B2 (en) 2018-02-27
EP2300018A1 (en) 2011-03-30
US20170368086A9 (en) 2017-12-28
AU2015242976A1 (en) 2015-11-05
US20090292238A1 (en) 2009-11-26
CA2725972A1 (en) 2010-11-11
EP2300018A4 (en) 2011-07-20
JP5507549B2 (ja) 2014-05-28
DK2300018T3 (en) 2017-09-11
US8491947B2 (en) 2013-07-23
EP2300018B1 (en) 2017-05-17
AU2009345773A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
US9901591B2 (en) Paeoniflorin preparations and uses thereof for fat reduction
US11344561B2 (en) Treatment of submental fat
TW201803561A (zh) 軟性抗膽鹼類似物之製劑
US20240299560A1 (en) Deoxycholic acid-peptide conjugate having anti-obesity activity and use thereof
CN102580087A (zh) 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法
KR20100023246A (ko) 레티노이드로 인한 피부자극 완화용 화장료 조성물
US20180055848A1 (en) Combination of Albuterol and Caffeine as Synergistic Treatment for Obesity or Sarcopenia
MX2014004362A (es) Preparado de huevo con propiedades regeneradoras, analgesicas y/o anti-inflamatorias.
KR20080097420A (ko) 티오우레아 유도체를 함유하는 소양성 또는 자극성피부질환의 예방 또는 치료용 외용제 조성물
HK1159477B (en) Paeoniflorin preparations and uses thereof for fat reduction
US20260041700A1 (en) IP-6 And Inositol Nerve Relaxing Transdermal Topical Cream, Gel, Or Ointment For Raynaud's Syndrome
KR102230271B1 (ko) 지방감소를 위한 글라이코데옥시콜릭산 (Glycodeoxycholic acid, GDCA)를 유효성분으로 포함하는 주사용 제제 및 조성물
Greenway et al. Anthropometry of local fat reduction
Raffa Analgesic patent applications: I
CN118021918A (zh) 防治血瘀证的精油组合物及其用途
US20070042998A1 (en) Medical cosmetic method for reducing adipose tissue and for initiating lipolysis through subcutaneous and intracutaneous injections and customized composition compounded from pharmaceutical agents for use therein
Beilin Body mesotherapy and ‘mesobotox’
CN102988338A (zh) 硝酸酯及其对肌肉和肌肉相关疾病的治疗用途
BERBECE et al. Use of Phosphatidylcholine in the Treatment of Localized Fat Deposits
Scherk et al. Analgesia for feline arthritis
Beilin 31 Body mesotherapy and
CN104940193A (zh) 一种含辛伐他汀的降血脂血糖药物组合物及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190906

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190906